These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 22535370

  • 1. Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.
    Fidan E, Kavgaci H, Orem A, Yilmaz M, Yildiz B, Fidan S, Akcan B, Ozdemir F, Aydin F.
    Tumour Biol; 2012 Oct; 33(5):1519-25. PubMed ID: 22535370
    [Abstract] [Full Text] [Related]

  • 2. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 3. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP, Schulman S, An SS, Greenfield RS, Blombäck M.
    Scand J Clin Lab Invest; 2004 Oct 01; 64(8):745-51. PubMed ID: 15719893
    [Abstract] [Full Text] [Related]

  • 4. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.
    Foley JH, Nesheim ME, Rivard GE, Brummel-Ziedins KE.
    Haemophilia; 2012 May 01; 18(3):e316-22. PubMed ID: 21933309
    [Abstract] [Full Text] [Related]

  • 5. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan 01; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 6. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
    Kemona-Chetnik I, Kowal K, Kucharewicz I, Pampuch A, Bodzenta-Lukaszyk A.
    Przegl Lek; 2006 Jan 01; 63(12):1281-5. PubMed ID: 17642140
    [Abstract] [Full Text] [Related]

  • 7. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways.
    So AK, Varisco PA, Kemkes-Matthes B, Herkenne-Morard C, Chobaz-Péclat V, Gerster JC, Busso N.
    J Thromb Haemost; 2003 Dec 01; 1(12):2510-5. PubMed ID: 14675085
    [Abstract] [Full Text] [Related]

  • 8. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.
    Sillen M, Declerck PJ.
    Int J Mol Sci; 2021 Apr 01; 22(7):. PubMed ID: 33916027
    [Abstract] [Full Text] [Related]

  • 9. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients.
    Hryszko T, Malyszko J, Malyszko JS, Brzosko S, Pawlak K, Mysliwiec M.
    Nephrol Dial Transplant; 2001 Aug 01; 16(8):1692-6. PubMed ID: 11477176
    [Abstract] [Full Text] [Related]

  • 10. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
    Bridge KI, Bollen L, Zhong J, Hesketh M, Macrae FL, Johnson A, Philippou H, Scott DJ, Gils A, Ariёns RAS.
    J Thromb Haemost; 2017 Nov 01; 15(11):2218-2225. PubMed ID: 28834317
    [Abstract] [Full Text] [Related]

  • 11. Thrombin activatable fibrinolysis inhibitor in preeclampsia and gestational hypertension throughout the gestation.
    Zhang Y, Hu Y, Guo T, Wei W, Zhang X.
    J Huazhong Univ Sci Technolog Med Sci; 2008 Apr 01; 28(2):140-3. PubMed ID: 18480982
    [Abstract] [Full Text] [Related]

  • 12. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 13. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb 01; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 14. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
    Małyszko J, Tymcio J.
    Pol Arch Med Wewn; 2008 Feb 01; 118(1-2):36-41. PubMed ID: 18405171
    [Abstract] [Full Text] [Related]

  • 15. [Thrombin activatable fibrinolysis o inhibitor-TAFI- in dialyzed patients with diabetic nephropathy].
    Małyszko JS, Małyszko J, Hryszko T, Myśliwiec M.
    Pol Arch Med Wewn; 2003 Aug 01; 110(2):843-8. PubMed ID: 14682222
    [Abstract] [Full Text] [Related]

  • 16. Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome.
    Pang H, Zhang C, Liu F, Gong X, Jin X, Su C.
    Med Intensiva; 2017 Nov 01; 41(8):475-482. PubMed ID: 28038785
    [Abstract] [Full Text] [Related]

  • 17. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May 01; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 18. Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer.
    Eser M, Kement M, Balin S, Coskun C, Kefeli U, Gumus M, Altuntas YE, Kurt N, Mayadagli A.
    World J Surg Oncol; 2012 Aug 31; 10():180. PubMed ID: 22938027
    [Abstract] [Full Text] [Related]

  • 19. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

  • 20. Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
    Coleman JR, Moore EE, Kelher MR, Jones K, Cohen MJ, Banerjee A, Silliman CC.
    J Trauma Acute Care Surg; 2023 Jun 01; 94(6):857-862. PubMed ID: 36787438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.